Prader Willi Syndrome
14
0
0
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.1%
1 terminated out of 14 trials
91.7%
+5.2% vs benchmark
7%
1 trials in Phase 3/4
9%
1 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (14)
Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact
Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Oxytocin Trial in Prader-Willi Syndrome
Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome
Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
Prader-Willi Syndrome Macronutrient Study
Post Exercise Irisin Levels in PWS Patients
Liraglutide Use in Prader-Willi Syndrome
Macronutrient Regulation of Ghrelin and Peptide YY
Hypoglycemia in Prader-Willi Syndrome
Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity
Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome